logo-loader
viewQ BioMed Inc.

Q BioMed marks another milestone with first patient dosed with Strontium89

It expects this to be the first of thousands of patients dosed with the FDA approved drug in the coming years

Q BioMed Inc. -
Strontium89, which can be administered every three months, has been shown in numerous clinical trials to relieve pain in over 70% of patients

Q BioMed Inc (OTCMKTS:QBIO), the biomedical group, has announced another milestone - the first patient dosing of its cancer bone pain drug Strontium89. 

The firm expects this to be the first of thousands of patients dosed with the FDA approved non-opioid drug in the coming years. 

"With an estimated 10 million people living with bone metastases, we expect that even a small penetration in this market will have dramatic effects on QBioMed’s future," said Q BioMed CEO Denis Corin. 

WATCH: Full interview: Q BioMed infuses first patient with its FDA-approved cancer bone pain drug

"We believe this drug has a very important role to play as clinicians move toward proven non-opioid therapeutics for pain palliation for patients with painful bone metastases."

This first dosing in a commercial setting comes after Q Biomed completed an initial commercial production run and shipment last month (February).

Due to the opioid crisis, clinicians and patients are looking for pain management alternatives. Strontium89, which can be administered every three months, was shown in numerous clinical trials to relieve pain in over 70% of patients who received the treatment.

Q BioMed plans to launch the drug in global markets, including Europe, later this year.

Contact the author at [email protected]

Quick facts: Q BioMed Inc.

Price: 1.845 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $41.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed activates its marketing campaign for its cancer bone pain drug

Q BioMed Inc (OTCQB:QBIO) Chief Commercialization Officer Kristin Keller tells Proactive the New York-based biotechnology firm has launched a marketing campaign for its non-opioid cancer bone pain drug Strontium89. Keller says the company has created a product website at Strontium89.com to...

2 weeks ago

2 min read